11:05 AM EDT, 04/28/2025 (MT Newswires) -- CG Oncology ( CGON ) on Monday reported durable long-term outcomes from its phase 3 Bond-003 trial evaluating cretostimogene grenadenorepvec in patients with high-risk non-muscle invasive bladder cancer, or NMIBC, unresponsive to Bacillus Calmette Guerin.

In Cohort C, 75.5% of patients achieved a complete response at any point during the study. At 24 months, 42.3% remained in complete response by Kaplan-Meier estimate, with 97.3% free from progression to muscle-invasive disease and 91.6% of initial responders remaining cystectomy-free.

Early results from Cohort P, in patients with BCG-unresponsive Ta/T1 disease without carcinoma in situ, showed a 90.5% high-grade recurrence-free survival rate at both three and nine months. Treatment was well-tolerated with no grade 3 or higher treatment-related adverse events reported.

The company is continuing to evaluate the therapy for potential regulatory submission.

Shares of CG Oncology ( CGON ) rose 34% in recent trading activity.

Price: 30.06, Change: +7.69, Percent Change: +34.38